X

Indication

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia... read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
› Email› Print

Aranesp® single-dose strengths can be combined to more precisely titrate doses and individualize anemia management for patients with CKD on dialysis

Aranesp® is also available in 150, 200, 300, and 500 mcg dose strengths.

The 10, 150, and 500 mcg dose strengths are available only as prefilled syringes.

Simply select one of the following doses to see which single-dose strengths may be combined to individualize anemia management

Select dose

120mсg

125mсg

10mсg

20mсg

25mсg

30mсg

35mсg

40mсg

45mсg

50mсg

55mсg

60mсg

65mсg

70mсg

75mсg

80mсg

85mсg

90mсg

95mсg

100mсg

105mсg

110mсg

115mсg

Dose Combination

-
mсg
30
mсg
65
mсg
10
mсg

Important Safety Information

  • Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria may occur with Aranesp®. Immediately and permanently discontinue Aranesp® if a serious allergic reaction occurs.
  • Blistering and skin exfoliation reactions including Erythema multiforme and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN), have been reported in patients treated with ESAs (including Aranesp®) in the postmarketing setting. Discontinue Aranesp® therapy immediately if a severe cutaneous reaction, such as SJS/TEN, is suspected.
  • Adverse reactions (≥ 10%) in Aranesp® clinical studies in patients with CKD were hypertension, dyspnea, peripheral edema, cough, and procedural hypotension.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease.